Lanzatech Global, Inc. (LNZAW) Stock Price & Analysis
Lanzatech Global, Inc. (LNZAW) rose 6.52% to USD 0.01 as of September 9, 2026 at 12:04 UTC, according to Nexqual real-time market data.
LNZAW last closed at USD 0.01; the session ranged USD 0.01–0.01 on volume of 8,272 shares. Market capitalization is —, with a 52-week range of USD 0.01–0.01 (NCM). Source: Nexqual, September 9, 2026 at 12:04 UTC.
Key Statistics (as of September 9, 2026 at 12:04 UTC)
| Price | USD 0.01 |
|---|---|
| Change | ▲ 6.52% (up) |
| Previous Close | USD 0.01 |
| Open | USD 0.02 |
| Day Range | USD 0.01 – 0.01 |
| 52-Week Range | USD 0.01 – 0.01 |
| Volume | 8,272 shares |
| Market Cap | — |
| Exchange | NCM |
Analyst Ratings (LNZAW)
Wall Street analysts rate LNZAW "None", per Nexqual as of September 9, 2026 at 12:04 UTC.
| Consensus Rating | None |
|---|
Earnings (LNZAW)
Source: Nexqual, September 9, 2026 at 12:04 UTC.
Financial Health Score (LNZAW)
Nexqual rates Lanzatech Global, Inc.'s overall financial health "Mixed" across five dimensions, as of September 9, 2026 at 12:04 UTC.
| Growth | Solid — Revenue +13% YoY (annual) |
|---|---|
| Profitability | Weak — Unprofitable, margin -87.7% |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Major Backers & Investors (LNZAW)
Notable institutional backers of Lanzatech Global, Inc. include Davidson Kempner Capital Management LP, Calamos Advisors LLC, CALAMOS INVESTMENT TRUST/IL-Calamos Market Neutral Income Fund, according to Nexqual as of September 9, 2026 at 12:04 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Davidson Kempner Capital Management LP | 5% |
| Calamos Advisors LLC | 4% |
| CALAMOS INVESTMENT TRUST/IL-Calamos Market Neutral Income Fund | 4% |
| Tenor Capital Management Co., L.p. | 3.14% |
| Q Global Advisors, LLC | 1.43% |
| LMR Partners LLP | 0.88% |
| Toronto Dominion Bank | 0.68% |
| Wolverine Asset Management, LLC | 0.58% |
Source: Nexqual, September 9, 2026 at 12:04 UTC.
From Lanzatech Global, Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Our Technology Platform Overview We have developed and deployed a flexible proprietary technology platform that integrates gas fermentation with upstream gasification and downstream product processing.
- Our proprietary process utilizes abundant, locally-sourced waste streams using existing infrastructure, turning off-gases into valuable commodities, while supporting the strategic objective of maximizing the productivity of industrial assets.
- To date, our technology has been deployed at six commercial plants, producing over 139 million gallons of fuel-grade ethanol.
- Our proprietary system produces multiple chemicals from diverse feedstocks using a single process, ensuring stability despite fluctuating gas compositions—unlike thermocatalytic methods.
Partnerships
- In June 2024, we extended our collaboration with LanzaJet and launched a joint offering with them called CirculAir™ which provides an end-to-end commercial solution utilizing LanzaTech's Gas Fermentation platform in conjunction with LanzaJet's ATJ platform to produce SAF and renewable diesel from a wide range of waste feedstocks, including industrial off gases, carbon dioxide and hydrogen, as well as gasified solids, such as municipal solid waste and residues from agriculture and forestry.
- LanzaJet assumed all of our obligations under the Battelle License Agreement, including development, reporting, royalty payment and sublicensing obligations. 14 The license granted by us to LanzaJet is exclusive, including as against us, with the exception of certain development projects we are undertaking in collaboration with the U.S.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| LNZA | LanzaTech Global, Inc. | USD 6.12 | ▼ 1.77% |
| MNTSW | Momentus Inc. | USD 0 | ▼ 63.16% |
| HUBCW | Hub Cyber Security Ltd. Warrant | USD 0.01 | ▲ 8.65% |
| CDIOW | Cardio Diagnostics Holdings, Inc. | USD 0.02 | ▲ 0% |
| REVBW | Revelation Biosciences, Inc. | USD 0.01 | ▲ 44.62% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 9, 2026 at 12:04 UTC. This page is informational and not investment advice.